Mersana Therapeutics (MRSN) executive Mandelia sold 1,791 shares for $1,128 at $0.63 under a 10b5-1 plan
Insider transactions reported
Ashish Mandelia (VP, Chief Accounting Officer at Mersana Therapeutics Inc., MRSN) reported that they sold 1,791 shares for $1,128 at $0.63, and acquired 4,783 shares between Jan 14, 2025 and Jan 15, 2025. After these transactions the filing shows 52,388 shares held directly.
- Reporting person
- Mandelia Ashish
- Role
- VP, Chief Accounting Officer
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jan 14, 2025 | Exercise or conversion of a derivative (M) | Common Stock1 | +4,783 | - | - | 54,179 direct |
| Jan 15, 2025 | Open-market sale (S) | Common Stock2 | -1,791 | $0.63 | $1,128 | 52,388 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jan 14, 2025 | Exercise or conversion of a derivative (M) | Restricted Stock UnitOn 4,783 Common Stock3, 4 | -4,783 | - | - | 4,783 direct |
Holdings before and after
- Common Stock: 49,396 to 52,388 direct
- Restricted Stock Unit: 9,566 to 4,783 direct
Footnotes from the filing
- 1. Represents shares of common stock received upon vesting of a portion of the restricted stock units ( RSUs ) awarded to the Reporting Person on January 14, 2022.
- 2. Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023. The sale was effected through an automatic sell to cover transaction that did not represent a discretionary trade by the Reporting Person.
- 3. Each RSU represents the contingent right to receive one share of common stock of the Issuer.
- 4. 25% of the total number of RSUs granted vested on January 14, 2025, and the remainder shall vest on January 14, 2026.
Transaction codes in this filing
- Open-market sale:
- Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
- Exercise or conversion of a derivative:
- Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
FAQ
What did Mandelia report in this MRSN Form 4?
Ashish Mandelia (VP, Chief Accounting Officer at Mersana Therapeutics Inc., MRSN) reported that they sold 1,791 shares for $1,128 at $0.63, and acquired 4,783 shares between Jan 14, 2025 and Jan 15, 2025. After these transactions the filing shows 52,388 shares held directly.
How many MRSN shares does Mandelia hold after this filing?
The filing shows 52,388 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
Was this MRSN insider sale made under a 10b5-1 plan?
The filing's footnotes mention a Rule 10b5-1 trading plan. Such a plan sets the terms of future trades in advance.
What does transaction code S mean on an SEC Form 4?
Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
Historical context for MRSN
Earlier insider filings at MRSN
- Jan 16, 2025SVP, Chief Sci.&Tech. Officer Lowinger Timothy B sold $1,130 worth of shares (1,794 units at $0.63) and converted options into 4,792 shares, increasing direct ownership by 1% to 245,930 units (SEC Form 4)
- Jan 16, 2025SVP, COO & CFO Deschuytner Brian converted options into 6,250 shares and sold $1,469 worth of shares (2,331 units at $0.63), increasing direct ownership by 4% to 109,030 units (SEC Form 4)
- Jan 16, 2025SVP, Chief Legal Officer Carvajal Alejandra converted options into 2,500 shares and sold $600 worth of shares (952 units at $0.63), increasing direct ownership by 2% to 70,892 units (SEC Form 4)
- Jan 16, 2025Director Protopapas Anna converted options into 31,250 shares and sold $7,612 worth of shares (11,534 units at $0.66), increasing direct ownership by 16% to 144,869 units (SEC Form 4)
- Jan 16, 2025VP, Chief Accounting Officer Mandelia Ashish converted options into 2,646 shares and sold $665 worth of shares (1,007 units at $0.66), increasing direct ownership by 3% to 49,396 units (SEC Form 4)
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2017
Follow MRSN and get a push notification the moment its next story breaks.